Metabolic syndrome with different antipsychotics: A multicentre cross-sectional study

Psychopharmacology Bulletin

Volumn 43, Issue 4, 2010, Pages 22-36

  Cerit, Cem ^a   Vural, Meltem ^a   Boşgelmez, Şükriye ^b   Özten, Eylem ^c   Aker, Ahmet Tamer ^c   Yildiz, Mustafa ^c  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b Derince State Hospital   (Turkey)

^c KOCAELI UNIVERSITY   (Turkey)

Author keywords

Antipsychotics; Metabolic risk; Metabolik syndrome; Side effects

Indexed keywords

CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZUCLOPENTHIXOL;

ARTICLE; BIPOLAR DISORDER; BLOOD PRESSURE MEASUREMENT; CROSS-SECTIONAL STUDY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MONOTHERAPY; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CHI-SQUARE DISTRIBUTION; CLOPENTHIXOL; CLOZAPINE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; TURKEY; YOUNG ADULT;

EID: 79953036902     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin resistance syndrome (Syndrome X). Diabetes. 1992;41:715-722.
2. (Adult Treatment Panel III 2001) Expert panel on detection and evaluation of treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA. 285:2486-2497.
3. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, Brussels, 2005.
4. Isomaa B, Almgren P,Tuomi T, Forsen B, Lahti K,Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689. (Pubitemid 32893993)
5. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population based study. Risk factor and life expectancy Research group. Am J Epidemiol. 1998;148:958-966.
6. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med. 2005;118 :15-22.
7. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68:20-27.
8. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32. (Pubitemid 41587460)
9. De Hert MA,Winkel RV, Eyck DV, Hansens L,Wampers M, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizoph Res. 2006;83:87-93.
10. Fagiolini A, Frank E, Scott JA,Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005:7:424-430. (Pubitemid 41419409)
11. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62:22-31. (Pubitemid 32402182)
12. Kabinoff GS, Toalson PA, Healey KM, Mc Guire HC, Hay DP. Metabolic issues with atypical antipsychotics in primary care: dispelling the myths. Prim Care Companion J Clin Psychiatry. 2003;5:6-14.
13. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006;67(4):575-583. (Pubitemid 43764234)
14. Bakos CD, Berecz R, Degrell I. Effect of atypical antipsychotics on metabolism. Neuropsychopharma Col Hung. 2004;6:86-89.
15. Correl CU, Fredericson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia Research. 2007;89:91-100. (Pubitemid 44881290)
16. Yumru M, SavaŞ HA, Kurt E, Kaya MC, Selek S, SavaŞ E, et al. Atypical antipsychotic related metabolic syndrome in bipolar patients. J Affect Disorders. 2007;98:247-252. (Pubitemid 46151723)
17. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19:1-93. (Pubitemid 40677047)
18. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856-865. (Pubitemid 35231725)
19. Tandon R, Jibson MD. Safety and tolerability: how do second generation atypical compare? Current Psychosis and Therapeutics Reports. 2003;1:15-21.
20. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology. 2006;186:572-578.
21. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008;10(7):788-797.
22. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry. 2004;6:74-77.
23. Almeras N, Despres JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry. 2004;65:557-564.
24. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin and blood lipids in olanzapine treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742-749.
25. Caballero E. Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy. CNS Spectr. 2003;8:19-22. (Pubitemid 38405537)
26. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, Mc Evoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atiypical antipsychotics. Am J Psychiatry. 2003;160:290-296. (Pubitemid 41110454)
27. Nasrallah HA, Newcomer JW. Atiypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standart of care. J Clin Psychopharmacol. 2004;24:7-14.
28. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161:1709-1711. (Pubitemid 39201473)
29. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm. 1996;53:2079-2081. (Pubitemid 26291959)
30. Spivak B, Lamschtein C, Talman Y. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol. 1999;22:98-101.
31. Spivak B, Roitman S,Vered Y. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol. 1998;21:245-250. (Pubitemid 28367078)
32. Henderson DC, Cagliero E, Gray C, Nasarallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five year naturalistic study. Am J Psychiatry. 2000;157:975-981. (Pubitemid 30412350)
33. Atmaca ve M, Kuloǧlu M, Tezcan E, Üstündaǧ B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598-604.